| Page 304 | Kisaco Research
WHIS 2024 Calander
 

Frank Shipp

Executive Director
Johns Hopkins CIN

Frank E. Shipp currently serves as Executive Director of the Johns Hopkins Clinical Alliance, the clinically integrated network of Johns Hopkins Medicine. The network includes over 3,000 providers, consisting of both employed and independent practices.

Frank Shipp

Executive Director
Johns Hopkins CIN

Frank Shipp

Executive Director
Johns Hopkins CIN

Frank E. Shipp currently serves as Executive Director of the Johns Hopkins Clinical Alliance, the clinically integrated network of Johns Hopkins Medicine. The network includes over 3,000 providers, consisting of both employed and independent practices.

Frank transitioned to value-based care after 25 years of hospital-based operations experience in both community and academic health systems. During the past nine years, Frank has held executive positions in a Payor-Provider Organization in NYC and has built a highly successful CIN over a five-year period in Northern New Jersey. Frank speaks regular at national healthcare conferences regarding value-based care strategies and tactics.

Frank completed his MBA at Fairleigh Dickinson University, is a certified Fellow of the American College of Healthcare Executives and a trained Black Belt in Lean Six Sigma from Villanova University.

 

Rena Bielinski

VP Customer Success
Codoxo

Rena Bielinski

VP Customer Success
Codoxo

Rena Bielinski

VP Customer Success
Codoxo
 

Jesse Montgomery

VP of Analytics and Data Science
Codoxo

Jesse Montgomery

VP of Analytics and Data Science
Codoxo

Jesse Montgomery

VP of Analytics and Data Science
Codoxo
  • Considerations for live-biotherapeutic development and applicability: reviewing microbiota variation, biomarkers, and metabolites.
  • Integrating a personalization approach to therapeutic discovery, linking clinical trial outcomes with in-vitro results obtained from the PMAS system.
  • How to harness the metabolome to guide the next generation of live-biotherapeutics.

Yosep Ji, Chief Executive Officer, HEM Pharma

Author:

Yosep Ji

Chief Executive Officer
HEM Pharma

Yosep Ji

Chief Executive Officer
HEM Pharma
  • Introduction to the current microbiome investment landscape and what direction investment is heading in over the next few years.
  • Highlighting what investors need to see from emerging companies, how are CSB evaluating companies.
  • How should microbiome companies adapt to trends and what should data packages contain.

Sou Miyake, Director of Investment & Business Development, Corundum Systems Biology

Author:

Sou Miyake

Director of Investment & Business Development
Corundum Systems Biology

Sou Miyake

Director of Investment & Business Development
Corundum Systems Biology
 

Kurt Nielsen

CEO
Partisia

Kurt is the CEO and co-founder of Partisia, a global leader in applied Secure Multi-Party Computation across applications and platforms. He holds a PhD in Economics and a part-time position as Associate Professor at the University of Copenhagen. As an experienced entrepreneur he has turned advanced cryptography solutions into innovative high-tech businesses for over 15 years e.g. as co-founder of Partisia, Sepior, and Partisia Blockchain.

Kurt Nielsen

CEO
Partisia

Kurt Nielsen

CEO
Partisia

Kurt is the CEO and co-founder of Partisia, a global leader in applied Secure Multi-Party Computation across applications and platforms. He holds a PhD in Economics and a part-time position as Associate Professor at the University of Copenhagen. As an experienced entrepreneur he has turned advanced cryptography solutions into innovative high-tech businesses for over 15 years e.g. as co-founder of Partisia, Sepior, and Partisia Blockchain.

 

Narendra Narang

Chief Account Technologist, Telecommunications
Red Hat

Narendra Narang

Chief Account Technologist, Telecommunications
Red Hat

Narendra Narang

Chief Account Technologist, Telecommunications
Red Hat